Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

Rhea-AI Summary

Natera, Inc. (NASDAQ: NTRA) has reached a significant milestone with over 200 peer-reviewed publications showcasing its cell-free DNA and genetic testing technology. The company's products have been featured in prestigious journals like Science and Nature, with notable studies in women's health, oncology, and organ health. Natera's commitment to scientific rigor and real-world clinical evidence underscores its dedication to improving patient outcomes.

Positive

• Natera has published over 200 peer-reviewed papers across various medical fields.
• The company's technology has been featured in top scientific journals like Science, Nature, and NEJM.
• Notable studies include SMART, the largest prospective NIPT study ever, and the GALAXY arm of the CIRCULATE-Japan trial.
• Natera's focus on cutting-edge science and data-driven tests demonstrates its commitment to transforming patient care.

Negative

• None.

Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomes

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature.

Landmark cutting-edge science and clinical trial data based on Natera’s suite of products have been published in top journals, such as Science, Nature, Nature Medicine, and New England Journal of Medicine (NEJM). This includes:

• More than 85 publications featuring Natera’s women’s health products, including data from SMART, the largest prospective NIPT study ever performed, with over 18,000 patients and confirmed genetic outcomes collected for all samples included in the analysis;
• More than 75 publications featuring Natera’s oncology products, including data from the GALAXY arm of the ongoing CIRCULATE-Japan trial, one of the largest and most comprehensive prospective studies of molecular residual disease testing in colorectal cancer; and
• Approximately 40 publications featuring Natera’s organ health products, including data from ProActive, the largest prospective donor-derived cfDNA study in kidney transplantation, and data from RenaCARE, a large, multisite, real-world, prospective study assessing the frequency and impact of genetic testing in chronic kidney disease.

“When it comes to transforming patient care, high-quality science and data drive everything,” said Alexey Aleshin, M.D., chief medical officer & general manager of oncology at Natera. “We have been very deliberate in making investments over the years to develop tests based on cutting-edge science – including some of the largest and most impactful studies ever to be performed in our field. We remain committed to generating evidence that supports the real-world impact of our innovations.”

About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 200 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.

Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, or our expectations of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240422167869/en/

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Source: Natera, Inc.

FAQ

How many peer-reviewed publications has Natera announced?

Natera has announced over 200 peer-reviewed publications.

In which journals have Natera's studies been featured?

Natera's studies have been featured in journals like Science, Nature, Nature Medicine, and NEJM.

What are some of the notable studies mentioned in the press release?

Notable studies include SMART, the largest prospective NIPT study ever, and data from the GALAXY arm of the CIRCULATE-Japan trial.

Who is the chief medical officer & general manager of oncology at Natera?

Alexey Aleshin, M.D., is the chief medical officer & general manager of oncology at Natera.